vicious circle of mutual activation between MM cells and OCL. 6 To evaluate MM cell-OCL interactions, we cocultured MM cells with human OCL. Whereas OCL and OPM-2 cells expressed the Notch1 protein, only OPM-2 cells coexpressed the Notch1 ligands Jagged1 and Delta (Figure 2a) . Analysis of mRNA expression of the Notch target Hes-1 in cocultured cells revealed no change in OPM-2 cells but a 2.3-fold increase in OCL (Figure 2a) , demonstrating the specific activation of Notch signaling in OCL cocultured with MM cells. To study whether increased Notch activity in OCL has functional consequences, we performed AnnexinV-FITC/PI staining and measured the induction of apoptosis after Notch inhibition in the OPM-2/OCL coculture system. As expected, Notch inhibition induced apoptosis of OPM-2 cells in mono-and coculture (Figure 2b Our data provide first-time evidence that Notch signaling is involved in specific tumor-stroma interactions between MM cells and primary OCL through direct cell-cell contact. We further demonstrate that this interaction is specific for OCL, as Notch signaling in OBL and MSC remains unaffected. Given that our findings in vitro are confirmed in myeloma models in vivo, use of GSI might become a novel therapeutic option in MM as we could demonstrate that they have antitumor effects (apoptosis induction) and suppress Notch-dependent OCL activity. We report three patients treated with intrathecal depocyte as part of post-remission therapy where spurious elevation of the CSF (cerebrospinous fluid) white cell count resulted from liposomes being passed as white cells by an automated cell counter. The first patient was a 55-year-old female with Burkitt leukaemia, who was treated according to the Magrath protocol with CODOX-M/IVAC chemotherapy with the addition of rituximab. Complete remission of disease was documented after Letters to the Editor the first course of treatment. On day 27 of cycle 2 the patient received a lumbar puncture, clear CSF was sent for a cell count and cytology as would be routine in our practice and intrathecal cytarabine (depocyte 50 mg) was given as part of CNS prophylaxis. The white cell count was markedly elevated in the three samples of CSF obtained, a Gram stain was negative and routine biochemistry was normal. A cytospin revealed multiple liposomes. The previous intrathecal depocyte administration was done 27 days earlier. The second patient, a 28-year-old male, was diagnosed with HIV associated Burkitt lymphoma following presentation with a lesion in his buccal mucosa. He had multiple cranial nerve palsies and a mixed peripheral and motor sensory neuropathy and a clinical diagnosis of CNS disease was made in the absence of objective involvement on imaging or repeated CSF analysis. He was commenced on treatment with the Magrath protocol with the addition of rituximab and anti-retroviral therapy. On cycle 3, a sample of clear CSF obtained immediately prior to administration of intrathecal depocyte revealed a high white cell count and cytology revealed similar liposomes to those seen in the first patient. Similar to the first case, there was no evidence of systemic or CNS disease progression. The previous intrathecal depocyte administration had been 14 days earlier. The last patient was a 36-year-old male who presented with standard risk acute myeloid leukaemia and was treated with conventional chemotherapy upfront. After 8 months following completion of primary therapy, he relapsed with CNS involvement following presentation with peripheral blood blasts, low back pain and sensory symptoms in his lower limbs. He achieved a second complete remission with one course of salvage therapy with FLAG and aggressive CNS directed therapy, which included liposomal cytarabine. As part of post-remission therapy CSF analysis prior to depocyte injection revealed elevated white cell counts in all the three samples obtained. The previous depocyte injection had been administered 2 weeks earlier. Once again, cytology demonstrated numerous liposomes.
Neoplastic meningitis has conventionally proven a difficult condition to treat, mainly because of the difficulty delivering drugs to the CNS. Most systemic chemotherapy agents only penetrate the CNS in small quantities at conventional doses. At high doses, sufficient quantities may reach the CSF, but at the expense of considerable systemic toxicity. For most intrathecal agents, clearance from the CSF is generally too rapid to ensure adequate distribution to sites distant from the point of injection. To deliver cytocidal concentrations of these agents to the CNS, frequent intrathecal dosing is necessary, which causes inconvenience for both the patient and the clinician.
Intrathecal depocyte is a formulation of cytarabine, where the active drug is suspended in the aqueous chambers of naturally occurring lipids (unpublished observations). After an intrathecal injection, the lipid particles disseminate throughout the neuraxis and slowly release cytarabine. A single injection of 50 mg of liposomal cytarabine maintains cytotoxic concentrations of cytarabine in the CSF for 414 days in most patients (CSF T1/2 ¼ 5.8 days). 1 The drug is uniformly distributed throughout the CSF. Furthermore, release into the systemic circulation is sufficiently slow, and metabolism by the liver sufficiently rapid, such that no cytarabine can be detected in plasma following intrathecal administration, thus allowing concomitant systemic chemotherapy to proceed uninterrupted.
The net effect is to produce better CNS clearance of disease in comparison with other agents, improved quality of life and delayed time to neurological progression. [2] [3] [4] It should be noted, however, that significant neurotoxicity will be observed in some patients, particularly those also receiving high-dose methotrexate as part of systemic therapy. 5 To date, the three patients described are the only reported cases in the literature where liposomes of cytarabine within the CNS have been mistakenly counted as white cells by an automated cell counter. In all three cases, there was no evidence of CNS or systemic disease at the time of sampling and intrathecal injections of depocyte had been administered 14-27 days prior to each reported case. Liposomes of depocyte range in size from 3-30 microns, correspondingly, mononuclear cells range from 12-20 microns in size and may have similar optical and physical properties to lipid particles, such that CSF liposomes may be passed as mononuclear cells by standard cell counters. Variations in lipid dimensions, clearance from the CSF and sampling technique may account for spuriously high cell counts in some patients getting depocyte and normal cell counts in others receiving the same drug. Given the more frequent usage of liposomal cytarabine in the treatment of malignant meningitis, it is important for clinicians to be aware of this phenomenon.
